This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.

How to buy TG Therapeutics stock | $29.52

Own TG Therapeutics stock in just a few minutes.

Posted

Fact checked

TG Therapeutics, Inc is a biotechnology business based in the US. TG Therapeutics shares (TGTX) are listed on the NASDAQ and all prices are listed in US Dollars. TG Therapeutics employs 217 staff and has a trailing 12-month revenue of around USD$152,000.

How to buy shares in TG Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for TG Therapeutics. Find the stock by name or ticker symbol: TGTX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until TG Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$29.52, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of TG Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of TG Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

TG Therapeutics share price

Use our graph to track the performance of TGTX stocks over time.

TG Therapeutics shares at a glance

Information last updated 2020-12-02.
Latest market close USD$29.52
52-week range USD$6.34 - USD$31.97
50-day moving average USD$28.4503
200-day moving average USD$23.8092
Wall St. target price USD$47.43
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.959

Buy TG Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy TG Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

TG Therapeutics price performance over time

Historical closes compared with the close of $29.52 from 2020-11-16

1 week (2020-11-25) 0.10%
1 month (2020-11-06) 4.64%
3 months (2020-09-04) 23.98%
6 months (2020-06-05) 61.49%
1 year (2019-12-05) 284.38%
2 years (2018-12-04) 490.40%
3 years (2017-12-05) 271.32%
5 years (2015-12-04) 109.07%

TG Therapeutics financials

Revenue TTM USD$152,000
Gross profit TTM USD$152,000
Return on assets TTM -76.52%
Return on equity TTM -318.55%
Profit margin 0%
Book value $1.434
Market capitalisation USD$3.6 billion

TTM: trailing 12 months

Shorting TG Therapeutics shares

There are currently 13.7 million TG Therapeutics shares held short by investors – that's known as TG Therapeutics's "short interest". This figure is 0.3% up from 13.7 million last month.

There are a few different ways that this level of interest in shorting TG Therapeutics shares can be evaluated.

TG Therapeutics's "short interest ratio" (SIR)

TG Therapeutics's "short interest ratio" (SIR) is the quantity of TG Therapeutics shares currently shorted divided by the average quantity of TG Therapeutics shares traded daily (recently around 1.3 million). TG Therapeutics's SIR currently stands at 10.38. In other words for every 100,000 TG Therapeutics shares traded daily on the market, roughly 10380 shares are currently held short.

However TG Therapeutics's short interest can also be evaluated against the total number of TG Therapeutics shares, or, against the total number of tradable TG Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case TG Therapeutics's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 TG Therapeutics shares in existence, roughly 100 shares are currently held short) or 0.1318% of the tradable shares (for every 100,000 tradable TG Therapeutics shares, roughly 132 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against TG Therapeutics.

Find out more about how you can short TG Therapeutics stock.

TG Therapeutics share dividends

We're not expecting TG Therapeutics to pay a dividend over the next 12 months.

Have TG Therapeutics's shares ever split?

TG Therapeutics's shares were split on a 100:5625 basis on 30 April 2012. So if you had owned 5625 shares the day before before the split, the next day you'd have owned 100 shares. This wouldn't directly have changed the overall worth of your TG Therapeutics shares – just the quantity. However, indirectly, the new 5525% higher share price could have impacted the market appetite for TG Therapeutics shares which in turn could have impacted TG Therapeutics's share price.

TG Therapeutics share price volatility

Over the last 12 months, TG Therapeutics's shares have ranged in value from as little as $6.34 up to $31.97. A popular way to gauge a stock's volatility is its "beta".

TGTX.US volatility(beta: 2.22)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while TG Therapeutics's is 2.2198. This would suggest that TG Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

TG Therapeutics overview

TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of various treatments for B-cell malignancies and autoimmune diseases. The company develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing. Its lead therapies include Umbralisib, an investigational dual inhibitor of PI3K delta and CK1 epsilon is being evaluated in phase 2b and phase 3 trials in patients with non-hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL); and Ublituximab, an investigational glycoengineered monoclonal antibody that targets a epitope on CD20-expressing B cells for patients with NHL, CLL, and relapsing forms of multiple sclerosis. In addition, the company develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. It is also has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A; Checkpoint Therapeutics, Inc.; Jiangsu Hengrui Medicine Co.; Novimmune SA; Ligand Pharmaceuticals Incorporated; and Jubilant Biosys. TG Therapeutics, Inc. is headquartered in New York, New York.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site